首页 > 最新文献

Future Virology最新文献

英文 中文
Molecular epidemiology of dengue virus circulating during 2021 outbreak in Pakistan 2021年巴基斯坦登革热疫情期间传播的登革热病毒分子流行病学
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-07-11 DOI: 10.2217/fvl-2022-0196
R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair
Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.
目的:目前的研究旨在确定2021年巴基斯坦重大疫情期间流行的登革热血清型。材料与方法:于2021年9 - 11月对来自不同省份的373份血清样本进行RT-PCR检测,进行血清型鉴定,并对部分登革热阳性样本进行部分序列分析。结果:373份样本中,登革热病毒阳性273份(73%),男性为主(61.9%)。DENV-2血清型完全占优势(99%),DENV-1血清型1例。测序数据显示在DENV-2巴基斯坦分离株中存在世界性基因型。结论:本研究强调了DENV-2在2021年暴发期间的持续优势,表明需要改进巴基斯坦的监测策略和媒介繁殖控制规划。
{"title":"Molecular epidemiology of dengue virus circulating during 2021 outbreak in Pakistan","authors":"R. Hakim, S. Bibi, Q. Ali, Bisma Sarfraz, Y. Arshad, Z. Rehman, M. Salman, A. Ikram, M. Umair","doi":"10.2217/fvl-2022-0196","DOIUrl":"https://doi.org/10.2217/fvl-2022-0196","url":null,"abstract":"Aim: The current study aimed to identify prevalent dengue serotypes during a major outbreak in 2021 in Pakistan. Materials & methods: From September-November 2021, 373 serum samples from different provinces were tested by RT-PCR for serotype identification, followed by partial sequence analysis of selected dengue-positive samples. Results: Out of 373 samples, 273 (73%) were positive for dengue virus infection with male predominance (61.9%). Complete predominance of DENV-2 serotype (99%) and a single case of DENV-1 was observed. Sequencing data revealed the presence of a cosmopolitan genotype within the DENV-2 Pakistani isolates. Conclusion: This study highlights the persistent predominance of DENV-2 during the 2021 outbreak, suggesting a need to improve surveillance strategies and vector breeding control programs in Pakistan.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42850592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach 朋友或敌人:大戟属与EB病毒和伯基特淋巴瘤的关联,一种计算机方法
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-07-07 DOI: 10.2217/fvl-2023-0011
E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel
Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.
目的:eb - barr病毒相关性伯基特淋巴瘤(BL)以EBNA1表达为特征。先前的研究假设伯基特淋巴瘤与大戟属的地方性之间存在相关性,而其他人则认为它具有抗病毒活性。方法:采用AutoDock Vina、GROMACS 2020.4和VEGA-QSAR进行计算机评价。结果:与EBNA1抑制剂VK0044相比,瑞香素具有更高的结合亲和力,保持稳定的配体RMSD值,并在EBNA1活性位点表现出最大的负结合能。结论:大戟属植物化学物质Daphnoretin对EBNA1具有较强的抑制作用,是一种有效的候选治疗药物。
{"title":"Friend or foe: association of Euphorbia spp. with Epstein–Barr virus and Burkitt's lymphoma, an in silico approach","authors":"E. Erdag, Ismet Ersalici, Cenk Serhan Ozverel","doi":"10.2217/fvl-2023-0011","DOIUrl":"https://doi.org/10.2217/fvl-2023-0011","url":null,"abstract":"Aim: Epstein–Barr virus-related Burkitt's lymphoma (BL) is characterized by EBNA1 expression. Previous studies have hypothesized a correlation between Burkitt's lymphoma and endemicity of Euphorbia spp. whereas others have suggested it possesses antiviral activity. We aimed to investigate the effect of Euphorbia spp. on BL. Methods: AutoDock Vina, GROMACS 2020.4 and VEGA-QSAR were used for in silico assessments. Results: Daphnoretin had a higher binding affinity than the EBNA1 inhibitor VK0044, maintained a steady ligand RMSD value and displayed the largest negative binding energy at the EBNA1 active site. Conclusion: Daphnoretin, a phytochemical of Euphorbia spp., had superior inhibitory activity of EBNA1 over other tested chemicals, suggesting it is an effective therapeutic drug candidate.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46463402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis 桥本甲状腺炎患者HHV-6A病毒载量与抗tpo抗体水平的相关性分析
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-07-07 DOI: 10.2217/fvl-2022-0194
Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani
Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.
目的:本研究探讨抗甲状腺过氧化物酶(anti-TPO)抗体水平与人类疱疹病毒6型(HHV-6)病毒载量之间的相关性,作为桥本甲状腺炎(HT)的诱因。材料与方法:本研究包括60名HT患者、60名非自身免疫性甲状腺疾病患者和60名甲状腺功能正常的受试者。使用实时PCR检测血清样本中的HHV-6病毒载量。结果:在HT患者血清样本中,病毒载量的增加与抗TPO抗体水平的增加之间存在显著相关性(p=0.001)。结论:本研究的目的是探索HHV-6A在HT发病中的潜在作用,目的是为受影响的个体确定改进的治疗方案。
{"title":"Correlation analysis of HHV-6A viral load and anti-TPO antibody levels in patients with Hashimoto's thyroiditis","authors":"Noorossadat Seyyedi, Fariba Esfandiyari, Gholamreza Rafiei Dehbidi, A. Farhadi, F. Zare, S. Namdari, Golrokh Bahmani, Banafsheh Rastegari, Farzaneh Zarghampoor, A. Behzad-Behbahani","doi":"10.2217/fvl-2022-0194","DOIUrl":"https://doi.org/10.2217/fvl-2022-0194","url":null,"abstract":"Aim: This study investigated the correlation between anti-thyroid peroxidase (anti-TPO) antibody levels and human herpesvirus 6 (HHV-6) viral load as triggers for Hashimoto's thyroiditis (HT). Materials & methods: The study included 60 HT patients, 60 patients with non-autoimmune thyroid disease, and 60 subjects with normal thyroid function. HHV-6 viral loads in serum samples were detected using real-time PCR. Results: A significant correlation was found between the increase in viral load and increased levels of anti-TPO antibodies in serum samples from HT patients (p = 0.001). Conclusion: The aim of this study was to explore the potential involvement of HHV-6A in the onset of HT, with the goal of identifying improved treatment options for affected individuals.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48157034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study 达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺治疗在意大利观察性队列中的有效性和安全性:DIAMANTE研究
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-06-22 DOI: 10.2217/fvl-2023-0065
A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti
Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )
目的:DIAMANTE是一项回顾性、前瞻性、非介入性队列研究,旨在描述达芦那韦/柯比司他/恩曲他滨/替诺福韦艾拉酚胺(D/C/F/TAF)在意大利实际临床实践中的有效性。患者和方法:该研究纳入246名患者:第1组包括接受达鲁那韦方案治疗的患者(n=81);第2组包括在D/C/F/TAF前接受不包括达芦那韦的抗逆转录病毒治疗的患者(n=43);第3组包括幼稚患者(n=122)。有效性评估为第48周的病毒学反应。结果:D/C/F/TAF病毒学应答率为72.1–78.8%,尽管由于2019冠状病毒大流行,随访间隔更长,但仍获得了应答。D/C/F/TAF的安全性良好,患者的总体满意度和生活质量也良好。结论:本研究证实了D/C/F/TAF在现实生活中的有效性和耐受性,包括在未接受达芦那韦治疗和未接受治疗的患者中。临床试验注册:NCT03577470(ClinicalTrials.gov)
{"title":"Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: the DIAMANTE study","authors":"A. Antinori, A. Vergori, D. Ripamonti, D. Valenti, G. Rizzardini, M. Cossu, S. Rusconi, V. Esposito, A. Cascio, G. Orofino, M. Andreoni, E. Manzillo, A. Castagna, D. Mancusi, R. Termini, Marianna Portaro, A. Uglietti","doi":"10.2217/fvl-2023-0065","DOIUrl":"https://doi.org/10.2217/fvl-2023-0065","url":null,"abstract":"Aim: DIAMANTE is a retrospective and prospective, non-interventional, cohort study to describe the effectiveness of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in real clinical practice in Italy. Patients & methods: The study enrolled 246 patients: group 1 included patients treated with a darunavir-based regimen (n = 81); group 2 included patients who received antiretroviral treatment not including darunavir before D/C/F/TAF (n = 43); and group 3 included naive patients (n = 122). Effectiveness was evaluated as the virological response at week 48. Results: The D/C/F/TAF virological response rate was 72.1–78.8% and was obtained despite longer follow-up intervals due to the coronavirus 2019 pandemic. The safety of D/C/F/TAF was good as was the overall patient satisfaction and quality of life. Conclusion: This study confirmed the effectiveness and tolerability of D/C/F/TAF in a real-life setting both in naive and pretreated patients, with and without darunavir. Clinical Trial Registration: NCT03577470 ( ClinicalTrials.gov )","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41745798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China 上海市92932例人乳头瘤病毒的流行及基因型分布
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-06-16 DOI: 10.2217/fvl-2022-0180
Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo
Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.
目的:人乳头瘤病毒(HPV)是宫颈上皮内瘤样病变(CIN)和癌症(CC)等高级别病变和致癌的最常见原因。不同地理区域HPV感染的患病率和基因型分布差异很大。患者与方法:本研究从2017年1月至2021年12月招募了92932名患者,并分析了HPV基因型的患病率和分布。结果:18038例(19.41%)HPV阳性。男性和女性之间的感染率没有显著差异(19.05比19.41%)。最常见的HPV亚型是HPV52、HPV58、HPV16、HPV53、HPV51和HPV81。在HPV阳性患者中,HPV的单一感染占主导地位。结论:我们的研究结果表明,HPV亚型的患病率和分布具有明显的区域特异性和年龄特异性特征。
{"title":"Prevalence and genotype distribution of human papillomavirus in 92,932 cases in Shanghai, China","authors":"Ya-Ping Hou, Cheng Fan, Qing-Qing Jiang, Lei Wu, Ying Luo","doi":"10.2217/fvl-2022-0180","DOIUrl":"https://doi.org/10.2217/fvl-2022-0180","url":null,"abstract":"Aim: Human papillomavirus (HPV) is the most common cause of high-grade lesions and carcinogenesis such as cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). The prevalence and genotype distribution of HPV infection varies greatly in different geographical areas. Patients & methods: This study enrolled 92,932 patients from January 2017 to December 2021 and analyzed the prevalence and distribution of HPV genotypes. Results: 18038 (19.41%) specimens were HPV-positive. No significant difference in infection rates between men and women (19.05 vs 19.41%). The most prevalent HPV subtypes are HPV52, HPV58, HPV16, HPV53, HPV51 and HPV81. Single infection of HPV has dominated in HPV-positive patients. Conclusion: Our results show that the prevalence and distribution of HPV subtypes have obvious region-specific and age-specific characteristics.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42220904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis 人类爱泼斯坦-巴尔病毒与脑癌的关系:一项系统综述和荟萃分析
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-06-05 DOI: 10.2217/fvl-2022-0219
S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani
Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.
目的:本研究的目的是调查eb病毒(EBV)感染与脑癌的总患病率及其潜在相关性。材料与方法:我们在主要数据库中检索相关研究,使用STATA软件V.14分析所有研究的异质性、优势比和相应的95% CI。结果:14篇文章被纳入meta分析。脑癌患者中EBV的总患病率为9% (95% CI: 3-16%;i2 = 91.06%)。EBV与脑癌之间存在关联(OR: 6.90 [95% CI: 1.81-26.28];i2 = 0%])。结论:本研究结果提示EBV感染与脑癌有显著相关性,提示EBV感染是脑癌发展的潜在危险因素。
{"title":"Association between human Epstein–Barr virus and brain cancer: a systematic review and meta-analysis","authors":"S. Ghorbani, Vahid Tambrchi, Rana Farzi, A. Khatami, Rahil Nahid Samiei, H. Saadati, M. Noori, Arash Letafati, Atefeh Bahavar, Noorin Hezarpishe, Mehrshid Musavioun, Bahareh Mirzaei, Mohadeseh Sadat Meftagh, Najme Khodaei Doust, Fatemeh Hejami, S. J. Kiani","doi":"10.2217/fvl-2022-0219","DOIUrl":"https://doi.org/10.2217/fvl-2022-0219","url":null,"abstract":"Aim: The aim of this study was to investigate the pooled prevalence and potential correlation between Epstein–Barr virus (EBV) infection and brain cancers. Materials & methods: We searched for relevant studies in main databases and analyzed the heterogeneity, odds ratio and corresponding 95% CI among all studies using STATA software V.14. Results: Fourteen articles were included in the meta-analysis. The pooled prevalence of EBV among brain cancer patients was 9% (95% CI: 3–16%; I2 = 91.06%). An association was found between EBV and brain cancer (OR: 6.90 [95% CI: 1.81–26.28]; I2 = 0%]). Conclusion: The results of this study indicate a significant association between EBV infection and brain cancer, suggesting EBV infection is a potential risk factor for brain cancer development.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46701399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Expression of TRIM56 gene in SARS-CoV-2 variants and its relationship with progression of COVID-19. TRIM56基因在SARS-CoV-2变异株中的表达及其与新冠肺炎进展的关系
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-06-01 Epub Date: 2023-07-13 DOI: 10.2217/fvl-2022-0210
Rezvan Tavakoli, Pooneh Rahimi, Mojtaba Hamidi-Fard, Sana Eybpoosh, Delaram Doroud, Iraj Ahmadi, Enayat Anvari, Mohammadreza Aghasadeghi, Abolfazl Fateh

Aim: The present study aimed to determine a correlation between differential TRIM56 expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants.

Materials & methods: This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of TRIM56 gene expression were determined using a qPCR.

Results: TRIM56 gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of TRIM56 mRNA expression in Delta and Omicron BA.5 variant, respectively.

Conclusion: Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.

目的:本研究旨在确定α、δ和Omicron BA.5变异之间TRIM56差异表达水平与COVID-19严重感染的相关性。材料与方法:本研究纳入330例COVID-19患者,其中重度感染142例,轻度感染188例,健康对照160例。采用qPCR检测TRIM56基因表达水平。结果:TRIM56基因在重度组和轻度组的mRNA表达量明显低于健康人。我们的发现表明TRIM56 mRNA在Delta和Omicron BA.5变体中分别有高和低的表达减少。结论:TRIM蛋白对COVID-19严重程度的影响有待进一步研究。
{"title":"Expression of <i>TRIM56</i> gene in SARS-CoV-2 variants and its relationship with progression of COVID-19.","authors":"Rezvan Tavakoli, Pooneh Rahimi, Mojtaba Hamidi-Fard, Sana Eybpoosh, Delaram Doroud, Iraj Ahmadi, Enayat Anvari, Mohammadreza Aghasadeghi, Abolfazl Fateh","doi":"10.2217/fvl-2022-0210","DOIUrl":"10.2217/fvl-2022-0210","url":null,"abstract":"<p><strong>Aim: </strong>The present study aimed to determine a correlation between differential <i>TRIM56</i> expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants.</p><p><strong>Materials & methods: </strong>This study was performed on 330 COVID-19 patients, including 142 with severe and 188 with mild infections, as well as 160 healthy controls. The levels of <i>TRIM56</i> gene expression were determined using a qPCR.</p><p><strong>Results: </strong><i>TRIM56</i> gene showed significantly lower mRNA expression in the severe and mild groups compared with healthy individuals. Our finding indicated the high and low reduction of <i>TRIM56</i> mRNA expression in Delta and Omicron BA.5 variant, respectively.</p><p><strong>Conclusion: </strong>Further research is needed to characterize the impact of TRIM proteins on the severity of COVID-19.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"1 1","pages":"563-574"},"PeriodicalIF":3.1,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41610222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond vaccination: prognostic value of p16-HPV testing in squamous cell cervical cancer 除疫苗接种外:p16-HPV检测在癌症鳞状细胞中的预后价值
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-05-23 DOI: 10.2217/fvl-2023-0074
Z. Dahbi
{"title":"Beyond vaccination: prognostic value of p16-HPV testing in squamous cell cervical cancer","authors":"Z. Dahbi","doi":"10.2217/fvl-2023-0074","DOIUrl":"https://doi.org/10.2217/fvl-2023-0074","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47604747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of nanotechnology in overcoming barriers to phage therapy: an overview 纳米技术在克服噬菌体治疗障碍中的作用:综述
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-05-22 DOI: 10.2217/fvl-2022-0229
Mehrdad Mohammadi, Mehrisadat Mirabadi, Masoumeh Beig, Somaieh Nasereslami, Mina Yazdanmehr, Fatemeh Monfared
Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.
由于抗生素耐药性的增加和对更可靠替代品的需求,噬菌体治疗再次受到欢迎。尽管有几项有希望的研究,噬菌体治疗的人类批准一直被推迟,因此,为了进入临床市场,必须消除现有的障碍,并开发新的解决方案。因此,纳米技术有可能帮助噬菌体配方克服它们的药理学缺陷。利用纳米技术改善噬菌体治疗在文献中得到的关注少得惊人。提高噬菌体在体内稳定性和滞留性的关键方法是包封。本文综述了纳米技术在噬菌体治疗方面的最新进展。
{"title":"The role of nanotechnology in overcoming barriers to phage therapy: an overview","authors":"Mehrdad Mohammadi, Mehrisadat Mirabadi, Masoumeh Beig, Somaieh Nasereslami, Mina Yazdanmehr, Fatemeh Monfared","doi":"10.2217/fvl-2022-0229","DOIUrl":"https://doi.org/10.2217/fvl-2022-0229","url":null,"abstract":"Phage treatment has again risen in popularity due to the rise of antibiotic resistance and the need for more reliable alternatives. Human approval of phage therapy has been delayed despite several promising investigations, so, in order to break into the clinical market, existing barriers must be eliminated, and new solutions must be developed. As such, nanotechnology has the potential to help phage formulations overcome their pharmacological drawbacks. The use of nanotechnology to improve phage therapy has received surprisingly little attention in the literature. The key method for increasing phage stability and retention inside the body is encapsulation. New developments in phage therapy using nanotechnology are summarized in this paper.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43807882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Identification of host factors that bind to the 5′ end of the MERS-CoV RNA genome 鉴定与MERS-CoV RNA基因组5 '端结合的宿主因子
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2023-05-22 DOI: 10.2217/fvl-2023-0070
Bader Y. Alhatlani, Waleed Aljabr, F. Alhamlan, A. Almatroudi, M. Azam, M. Alsaleem, K. Allemailem
Aim: The aim of this study was to identify host factors that interact with the 5′ end of the MERS-CoV RNA genome. Materials & methods: RNA affinity chromatography followed by mass spectrometry analysis was used to identify the binding of host factors in Vero E6 cells. Results: A total of 59 host factors that bound the MERS-CoV RNA genome in non-infected Vero E6 cells were identified. Most of the identified cellular proteins were previously reported to interact with the genome of other RNA viruses. We validated our mass spectrometry results using western blotting. Conclusion: These data enhance our knowledge about the RNA–host interactions of coronaviruses, which could serve as targets for developing antiviral therapeutics against MERS-CoV.
目的:本研究的目的是鉴定与MERS-CoV RNA基因组5′端相互作用的宿主因子。材料与方法:采用RNA亲和色谱法和质谱分析法对Vero E6细胞中宿主因子的结合进行鉴定。结果:在未感染的Vero E6细胞中,共鉴定出59个与MERS-CoV RNA基因组结合的宿主因子。大多数已鉴定的细胞蛋白先前被报道与其他RNA病毒的基因组相互作用。我们使用蛋白质印迹法验证了我们的质谱结果。结论:这些数据增强了我们对冠状病毒的RNA-宿主相互作用的了解,可以作为开发针对MERS-CoV的抗病毒疗法的靶点。
{"title":"Identification of host factors that bind to the 5′ end of the MERS-CoV RNA genome","authors":"Bader Y. Alhatlani, Waleed Aljabr, F. Alhamlan, A. Almatroudi, M. Azam, M. Alsaleem, K. Allemailem","doi":"10.2217/fvl-2023-0070","DOIUrl":"https://doi.org/10.2217/fvl-2023-0070","url":null,"abstract":"Aim: The aim of this study was to identify host factors that interact with the 5′ end of the MERS-CoV RNA genome. Materials & methods: RNA affinity chromatography followed by mass spectrometry analysis was used to identify the binding of host factors in Vero E6 cells. Results: A total of 59 host factors that bound the MERS-CoV RNA genome in non-infected Vero E6 cells were identified. Most of the identified cellular proteins were previously reported to interact with the genome of other RNA viruses. We validated our mass spectrometry results using western blotting. Conclusion: These data enhance our knowledge about the RNA–host interactions of coronaviruses, which could serve as targets for developing antiviral therapeutics against MERS-CoV.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48682635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Future Virology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1